Inhibition of Pseudomonas Aeruginosa Secreted Virulence Factors Reduces Lung Inflammation in CF Mice

Overview

Journal Virulence

Specialty Microbiology

Date 2018 Jun 26

PMID 29938577

Citations 16

Authors

Angela Sandri

Alessia Ortombina

Federico Boschi

Eleonora Cremonini

Marzia Boaretti

Claudio Sorio

Paola Melotti

Gabriella Bergamini

Maria Lleo

Affiliations

Soon will be listed here.

Abstract

Background: Cystic fibrosis (CF) lung infection is a complex condition where opportunistic pathogens and defective immune system cooperate in developing a constant cycle of infection and inflammation. The major pathogen, Pseudomonas aeruginosa, secretes a multitude of virulence factors involved in host immune response and lung tissue damage. In this study, we examined the possible anti-inflammatory effects of molecules inhibiting P. aeruginosa virulence factors.

Methods: Pyocyanin, pyoverdine and proteases were measured in bacterial culture supernatant from different P. aeruginosa strains. Inhibition of virulence factors by sub-inhibitory concentrations of clarithromycin and by protease inhibitors was evaluated. Lung inflammatory response was monitored by in vivo bioluminescence imaging in wild-type and CFTR-knockout mice expressing a luciferase gene under the control of a bovine IL-8 promoter.

Results: The amount of proteases, pyocyanin and pyoverdine secreted by P. aeruginosa strains was reduced after growth in the presence of a sub-inhibitory dose of clarithromycin. Intratracheal challenge with culture supernatant containing bacteria-released products induced a strong IL-8-mediated response in mouse lungs while lack of virulence factors corresponded to a reduction in bioluminescence emission. Particularly, sole inactivation of proteases by inhibitors Ilomastat and Marimastat also resulted in decreased lung inflammation.

Conclusions: Our data support the assumption that virulence factors are involved in P. aeruginosa pro-inflammatory action in CF lungs; particularly, proteases seem to play an important role. Inhibition of virulence factors production and activity resulted in decreased lung inflammation; thus, clarithromycin and protease inhibitors potentially represent additional therapeutic therapies for P. aeruginosa-infected patients.

Citing Articles

Exploring Proteases as Alternative Molecular Targets to Tackle Inflammation in Cystic Fibrosis Respiratory Infections.

Sandri A, Boschi F Int J Mol Sci. 2025; 26(5).

PMID: 40076497 PMC: 11899166. DOI: 10.3390/ijms26051871.

Antibiofilm activity of species from the cystic fibrosis lung microbiota against .

Grassi L, Asfahl K, Van den Bossche S, Maenhout I, Sass A, Vande Weygaerde Y Biofilm. 2024; 7:100206.

PMID: 38975276 PMC: 11225020. DOI: 10.1016/j.bioflm.2024.100206.

In Vivo Inflammation Caused by spp. Cystic Fibrosis Clinical Isolates Exhibiting Different Pathogenic Characteristics.

Sandri A, Saitta G, Veschetti L, Boschi F, Mantovani R, Carelli M Int J Mol Sci. 2023; 24(8).

PMID: 37108596 PMC: 10139000. DOI: 10.3390/ijms24087432.

: Infections, Animal Modeling, and Therapeutics.

Wood S, Kuzel T, Shafikhani S Cells. 2023; 12(1).

PMID: 36611992 PMC: 9818774. DOI: 10.3390/cells12010199.

Inhibition of Quorum Sensing and Virulence Factors of by Biologically Synthesized Gold and Selenium Nanoparticles.

Elshaer S, Shaaban M Antibiotics (Basel). 2021; 10(12).

PMID: 34943673 PMC: 8698379. DOI: 10.3390/antibiotics10121461.

References

Hogardt M, Heesemann J . Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int J Med Microbiol. 2010; 300(8):557-62. DOI: 10.1016/j.ijmm.2010.08.008. View

Nenan S, Lagente V, Planquois J, Hitier S, Berna P, Bertrand C . Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007; 559(1):75-81. DOI: 10.1016/j.ejphar.2006.11.070. View

Samson C, Tamalet A, Vu Thien H, Taytard J, Perisson C, Nathan N . Long-term effects of azithromycin in patients with cystic fibrosis. Respir Med. 2016; 117:1-6. DOI: 10.1016/j.rmed.2016.05.025. View

Pukhalsky A, Shmarina G, Kapranov N, Kokarovtseva S, Pukhalskaya D, Kashirskaja N . Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm. 2004; 13(2):111-7. PMC: 1781547. DOI: 10.1080/09629350410001688495. View

Suntres Z, Omri A, Shek P . Pseudomonas aeruginosa-induced lung injury: role of oxidative stress. Microb Pathog. 2002; 32(1):27-34. DOI: 10.1006/mpat.2001.0475. View

Yalcin E, Kiper N, Ozcelik U, Dogru D, Firat P, Sahin A . Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther. 2006; 31(1):49-55. DOI: 10.1111/j.1365-2710.2006.00708.x. View

Grobelny D, Poncz L, Galardy R . Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992; 31(31):7152-4. DOI: 10.1021/bi00146a017. View

Pilcer G, Rosiere R, Traina K, Sebti T, Vanderbist F, Amighi K . New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J Pharm Sci. 2013; 102(6):1836-1846. DOI: 10.1002/jps.23525. View

Hall S, McDermott C, Anoopkumar-Dukie S, McFarland A, Forbes A, Perkins A . Cellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosa. Toxins (Basel). 2016; 8(8). PMC: 4999852. DOI: 10.3390/toxins8080236. View

10.

Hobden J . Pseudomonas aeruginosa proteases and corneal virulence. DNA Cell Biol. 2002; 21(5-6):391-6. DOI: 10.1089/10445490260099674. View

11.

Dogru D, Dalgic F, Kiper N, Ozcelik U, Yalcin E, Tana Aslan A . Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status. Turk J Pediatr. 2010; 51(5):416-23. View

12.

Kobayashi T, Tateda K, Matsumoto T, Miyazaki S, Watanabe A, Nukiwa T . Macrolide-treated Pseudomonas aeruginosa induces paradoxical host responses in the lungs of mice and a high mortality rate. J Antimicrob Chemother. 2002; 50(1):59-66. DOI: 10.1093/jac/dkf048. View

13.

Nadal Jimenez P, Koch G, Thompson J, Xavier K, Cool R, Quax W . The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol Mol Biol Rev. 2012; 76(1):46-65. PMC: 3294424. DOI: 10.1128/MMBR.05007-11. View

14.

Kipnis E, Sawa T, Wiener-Kronish J . Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect. 2006; 36(2):78-91. DOI: 10.1016/j.medmal.2005.10.007. View

15.

Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K . Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med. 2003; 97(7):844-50. DOI: 10.1016/s0954-6111(03)00042-8. View

16.

Robinson P, Schechter M, Sly P, Winfield K, Smith J, Brennan S . Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Pediatr Pulmonol. 2012; 47(6):551-7. DOI: 10.1002/ppul.21613. View

17.

Gloyne L, Grant G, Perkins A, Powell K, McDermott C, Johnson P . Pyocyanin-induced toxicity in A549 respiratory cells is causally linked to oxidative stress. Toxicol In Vitro. 2011; 25(7):1353-8. DOI: 10.1016/j.tiv.2011.05.004. View

18.

Johansen H, Hoiby N . Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax. 1992; 47(2):109-11. PMC: 463585. DOI: 10.1136/thx.47.2.109. View

19.

Travis J, Potempa J . Bacterial proteinases as targets for the development of second-generation antibiotics. Biochim Biophys Acta. 2000; 1477(1-2):35-50. DOI: 10.1016/s0167-4838(99)00278-2. View

20.

Tagaya E, Tamaoki J, Kondo M, Nagai A . Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest. 2002; 122(1):213-8. DOI: 10.1378/chest.122.1.213. View